{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:12:56Z","timestamp":1793056376675,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"DOI":"10.1007\/s42000-026-00766-3","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:49:07Z","timestamp":1775141347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gonadal recovery in men with prolactinomas on cabergoline: 6-month testosterone levels as a predictor of testosterone replacement timing"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-3743","authenticated-orcid":false,"given":"Neslihan Koray","family":"Fedai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagihan","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayri","family":"Bostan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Kizilgul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"Cakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir","family":"Ucan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"6","key":"766_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11596-022-2673-6","volume":"42","author":"XY Wan","year":"2002","unstructured":"Wan XY, Chen J, Wang JW, Liu YC, Shu K, Lei T (2002) Overview of the 2022 WHO classification of pituitary Adenomas\/Pituitary neuroendocrine tumors: clinical Practices, Controversies, and perspectives. Curr Med Sci 42(6):1111\u20131118. https:\/\/doi.org\/10.1007\/s11596-022-2673-6","journal-title":"Curr Med Sci"},{"issue":"1","key":"766_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","volume":"23","author":"H Duskin-Bitan","year":"2020","unstructured":"Duskin-Bitan H, Shimon I (2020) Prolactinomas in males: any differences? Pituitary 23(1):52\u201357. https:\/\/doi.org\/10.1007\/s11102-019-01009-y","journal-title":"Pituitary"},{"key":"766_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/bs.vh.2024.11.001","volume":"129","author":"Y Rudman","year":"2025","unstructured":"Rudman Y, Shimon I (2025) Hypogonadism in men with prolactinoma: Diagnosis, treatment, and management of persistent hypogonadism. Vitam Horm 129:185\u2013202. https:\/\/doi.org\/10.1016\/bs.vh.2024.11.001","journal-title":"Vitam Horm"},{"issue":"12","key":"766_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"766_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"De Rosa M, Ciccarelli A, Zarrilli S et al (2006) The treatment with Cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64(3):307\u2013313. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02461.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"766_CR6","doi-asserted-by":"publisher","first-page":"dgaa650","DOI":"10.1210\/clinem\/dgaa650","volume":"105","author":"M Sehemby","year":"2020","unstructured":"Sehemby M, Lila AR, Sarathi V et al (2020) Predictors of chronic LH-Testosterone axis suppression in male macroprolactinomas with normoprolactinemia on Cabergoline. J Clin Endocrinol Metab 105(12):dgaa650. https:\/\/doi.org\/10.1210\/clinem\/dgaa650","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"766_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","volume":"25","author":"Y Rudman","year":"2022","unstructured":"Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon (2022) Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6):882\u2013890. https:\/\/doi.org\/10.1007\/s11102-022-01259-3","journal-title":"Pituitary"},{"issue":"4","key":"766_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11102-022-01242-y","volume":"25","author":"KM Al Dahmani","year":"2022","unstructured":"Al Dahmani KM, Almalki MH, Ekhzaimy A et al (2022) Proportion and predictors of hypogonadism recovery in men with macroprolactinomas treated with dopamine agonists. Pituitary 25(4):658\u2013666. https:\/\/doi.org\/10.1007\/s11102-022-01242-y","journal-title":"Pituitary"},{"issue":"5","key":"766_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","volume":"27","author":"SM Constantinescu","year":"2024","unstructured":"Constantinescu SM, Maiter D, Alexopoulou O (2024) Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists. Pituitary 27(5):625\u2013634. https:\/\/doi.org\/10.1007\/s11102-024-01445-5","journal-title":"Pituitary"},{"issue":"10","key":"766_CR10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","volume":"13","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S (2025) Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 13(10):874\u2013890. https:\/\/doi.org\/10.1016\/S2213-8587(25)00227-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"766_CR11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR et al (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715\u20131744. https:\/\/doi.org\/10.1210\/jc.2018-00229","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"766_CR12","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"766_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jcem-64-2-391","volume":"64","author":"JC Prior","year":"1987","unstructured":"Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for Estrogen. J Clin Endocrinol Metab 64(2):391\u2013394. https:\/\/doi.org\/10.1210\/jcem-64-2-391","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"766_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-025-01512-5","volume":"28","author":"H Bostan","year":"2025","unstructured":"Bostan H, Ucan B, Duger H et al (2025) Good response rates and predictors during the first year of Cabergoline treatment in large invasive prolactinomas. Pituitary 28(2):38. https:\/\/doi.org\/10.1007\/s11102-025-01512-5","journal-title":"Pituitary"},{"issue":"2","key":"766_CR15","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"766_CR16","doi-asserted-by":"publisher","first-page":"S294","DOI":"10.4103\/2230-8210.104064","volume":"16","author":"A Rastogi","year":"2012","unstructured":"Rastogi A, Walia R, Dutta P, Bhansali A (2012) Efficacy and safety of rapid escalation of Cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial. Indian J Endocrinol Metab 16(Suppl 2):S294\u2013S296. https:\/\/doi.org\/10.4103\/2230-8210.104064","journal-title":"Indian J Endocrinol Metab"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00766-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:49:08Z","timestamp":1775141348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00766-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":16,"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00766-3","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Ministry of Health, Ankara Etlik City Hospital (Approval No: AE\u015eH-BADEK2-2025-313).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}